Startup profile · funding coverage
WhiteLab Genomics funding, valuation and investors
TechBio company using AI to design delivery systems and genetic payloads for genomic medicines.
Keep track of WhiteLab Genomics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$26M · October 6, 2026
Latest known valuation
Undisclosed
Series B · October 6, 2026
Total disclosed equity funding
$26M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Paris, France and Boston, Massachusetts, United States
Investors in latest funding
Lead: AVP
Other: Yaday Health , Blast Club , Omnes Capital , Debiopharm Innovation Fund
Overview
WhiteLab Genomics combines computational design with biological validation to create delivery technologies and payloads for cell and gene therapies.
Why WhiteLab Genomics is interesting
The company is moving from computational services toward proprietary bio-assets, increasing licensing upside while accepting greater preclinical and development risk.
Product & use cases
Its ALFRED platform supports the design of vectors, delivery systems and payloads that WhiteLab intends to validate and license as genomic-medicine assets.
- AI design of genomic delivery systems
- Genetic payload optimization
- Preclinical bio-asset development and licensing
Key facts
- Closed a $26M Series B led by AVP.
- Plans to fund preclinical validation and international expansion.
Funding history (newest first)
Series B
2026-10-06 $26M Valuation: Undisclosed- AVP (lead)
- Yaday Health (participant)
- Blast Club (participant)
- Omnes Capital (participant)
- Debiopharm Innovation Fund (participant)
Investors in our directory
Funds linked from WhiteLab Genomics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: A computational platform connected to biological validation and a growing portfolio of owned delivery and payload assets.
Competes with gene-delivery design companies, AI drug-discovery platforms and internal pharmaceutical computational-biology teams.
-
Dyno Therapeutics direct
AI-designed gene-delivery capsids.
-
Generate Biomedicines adjacent
Machine-learning-designed biological therapeutics.
-
VectorY adjacent
Vectorized antibody and gene-therapy development.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover WhiteLab Genomics's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.